Published On: Tue, Mar 30th, 2021

Biocon, Libbs Farmaceutica team up for launching generic drugs in Brazil

Tagged with: | | | | | | |

Biocon Ltd, an Indian biopharma company, has entered into a partnership with Brazilian pharma company Libbs Farmaceutica for launching generic drugs in Brazil.

The company will be represented in the partnership by its fully-owned subsidiary Biocon Pharma.

The partnership marks the foray of Biocon’s generic formulations into the Latin American region. It consolidates on the company’s association with Libbs Farmaceutica, which started in 2017 for launching biosimilar Trastuzumab in Brazil.

Siddharth Mittal – CEO and Managing Director of Biocon said: “Expanding our association with Libbs Farmaceutica, a trusted partner, to our generic formulations, will help us establish a firm footing in Latin America, starting with Brazil.

“We remain committed to expanding our global presence with high-quality and affordable medicines and invest in strengthening capabilities that enable us to serve patients globally.”

Biocon, Libbs Farmaceutica team up for launching generic drugs in Brazil

Biocon, Libbs Farmaceutica team up for launching generic drugs in Brazil. Photo courtesy of Biocon.

Under the terms of the out-licensing deal with Libbs Farmaceutica, the Indian biopharma company will handle drug development and manufacturing. On its part, Libbs Farmaceutica will utilize its deep expertise and presence in Brazil for importing, distributing, and marketing the generic drugs.

The partnership deal will be subject to approvals from ANVISA, the Brazilian health regulatory agency.

– Libbs Farmaceutica Executive President said: “We are very happy with this partnership that is going to make a difference in our patients’ lives. We started with years ago, and we were very successful: our Trastuzumab became a leader in the private market, a milestone for our company.

“We will now continue making a difference in people’s lives with Biocon, with the goal to expand access to quality, safe and effective treatments to our patients.”

Related posts